Page 7 - Venetoclax Venclexta News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Venetoclax venclexta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Venetoclax Venclexta Today - Breaking & Trending Today

SLS009 Plus Venetoclax/Azacitidine Displays Activity, Tolerability in Relapsed/Refractory AML

The addition of SLS009 to the combination of venetoclax and azacitidine produced anti-leukemic effects and was safe in patients with relapsed/refractory acute myeloid leukemia who did not respond or stopped responding to venetoclax-based therapies. ....

United States , Angelos Stergiou , Omer Jamy , Oneal Comprehensive Cancer Center , University Of Alabama At Birmingham , Bone Marrow Transplant Program , O Neal Comprehensive Cancer Center , Hematologic Oncology , Acute Myeloid Leukemia ,

Dr Allan on the Investigation of Obinutuzumab Triplet Consolidation in MRD-Positive CLL

John N. Allan, MD, discusses a planned evaluation of obinutuzumab triplet consolidation therapy for patients with chronic lymphocytic leukemia /small lymphocytic lymphoma who remain minimal residual disease–positive after initial treatment with zanubrutinib and venetoclax . ....

Johnn Allan , International Workshop , Division Of Hematology , Medical Oncology , Weill Cornell Medicine , Minimal Residual Disease Mrd Positive , Obinutuzumab Triplet Consolidation Therapy , Chronic Lymphocytic Leukemia Small Lymphoma ,

Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS

The addition of bexmarilimab to standard-of-care azacitidine or azacitidine plus venetoclax continued to elicit responses in patients with relapsed or refractory acute myeloid leukemia and those with myelodysplastic syndrome who were refractory to hypomethylating agents. ....

United States , Markku Jalkanen , Faron Pharmaceuticals , Faron Pharmaceuticals Ltd , International Prognostic Scoring System , Bayesian Optimal Interval , Rr Aml , Relapsed Or Refractory Acute Myeloid Leukemia , Hypomethylating Agents , Phase 1 2 Bexmab Study Nct05428969 ,

Venetoclax Plus Dexamethasone Misses PFS End Point in t(11;14)+ R/R Multiple Myeloma

The combination of venetoclax and dexamethasone failed to significantly improve progression-free survival over pomalidomide plus dexamethasone in patients with t(11;14)-positive, relapsed or refractory multiple myeloma who have previously received at least 2 therapies. ....

San Diego , United States , Noord Holland , Venclexta Venclyxto , Mariana Cota Stirner , International Myeloma Working Group , European Hematology Association Congress , With Pomdex , Cota Stirner , Dimopoulosm A , Hematology Association Congress , Phase 3 Canova Study ,

Venetoclax and Rituximab Combination Maintains Survival Benefit in Relapsed/Refractory CLL

Patients with relapsed/refractory chronic lymphocytic leukemia achieved sustained progression-free survival and overall survival benefit after treatment with fixed-duration venetoclax plus rituximab vs bendamustine plus rituximab, according to data from the phase 3 MURANO trial. ....

United States , International Workshop , Venetoclax Plus Rituximab , Chronic Lymphocytic Leukemia , Murano Trial , International Workshop On Cll , Johnf Seymour , Peter Maccallum Cancer Centre , Royal Melbourne Hospital ,